Introduction
============

Boron is a naturally occurring element, representing 0.001% of the Earth\'s crust ([@b1-or-42-01-0115]). Borax, which is also known as sodium tetraborate decahydrate (Na~2~B~4~O~7~10H~2~O), is an important boron compound ([@b2-or-42-01-0115]). In animals and humans, borax has been reported to be involved in metabolic processes associated with hormones and minerals ([@b3-or-42-01-0115]). It has also been demonstrated to possess anti-inflammatory activity, indicating its therapeutic potential ([@b4-or-42-01-0115],[@b5-or-42-01-0115]). Boron supplementation in the diet (borax, 100 mg/kg) has also been implicated to decrease lipid peroxidation and enhance antioxidant defense ([@b6-or-42-01-0115]). Previous studies have suggested that the mechanism underlying the anti-inflammatory properties of borax involved the suppression of interleukin (caspase-)-8, indicating that borax is potentially applicable for a bactericidal agent ([@b7-or-42-01-0115],[@b8-or-42-01-0115]). However, numerous studies exploring the mutagenic properties of borax reported that its genotoxicity was nearly undetectable in bacteria and cultured mammalian cells ([@b9-or-42-01-0115],[@b10-or-42-01-0115]). Furthermore, previous studies revealed that different concentrations of borax affected cell survival and cell growth in addition to altering the properties of a few chromosomes in humans, which were possibly caused by various genetic defects resulting from abnormalities in human chromosome ([@b11-or-42-01-0115],[@b12-or-42-01-0115]). Additionally, borax has been widely known to have detrimental effects on lymphocyte proliferation, which is also highly vulnerable to induced sister chromatid exchange in human chromosomes ([@b13-or-42-01-0115]). Thus, certain cellular toxicities indicated that those alterations were ascribed to genetic defects caused by borax in humans ([@b14-or-42-01-0115]). Notably, it has been recently identified that borax treatment enhanced the resistance of DNA to titanium dioxide-induced damage ([@b15-or-42-01-0115]). Taken together, numerous studies have focused on the application of borax for tumor prevention and demonstrated a strong inverse correlation between borax and various types of cancer, including prostate cancer, lung cancer, cervical cancer and hepatocellular carcinoma (HCC) ([@b6-or-42-01-0115]--[@b15-or-42-01-0115]). Although increasing studies have revealed various functions for borax, the underlying mechanisms of those effects remain unidentified, in particular regarding its genetic influences on various cells.

Our previous results indicated the effects of borax on tumor cells (HepG2) *in vitro* (Wu *et al* unpublished data). It was revealed that caspase\--6 expression was increased following 2-h borax treatment in HepG2 cells and cell proliferation was inhibited following 24-h borax (4 mM) treatment. The numbers of living HepG2 cells and the borax concentrations were inversely correlated. Additionally, the 50% inhibitory concentration of borax was estimated as 4 mM ([@b16-or-42-01-0115]). Although borax can be genotoxic at high doses, it is not highly mutagenic and does not easily form DNA adducts ([@b17-or-42-01-0115]). Accordingly, borax is considered to induce oxidative stress through the depletion of glutathione and protein-bound sulfhydryl groups, which results in enhanced apoptosis and the production of reactive oxygen species ([@b18-or-42-01-0115],[@b19-or-42-01-0115]). In brief, borax is predominately non-genotoxic and epigenetic mechanisms are likely to underlie the mechanism for its induction of carcinogenesis, during which the expression of multiple essential genes are altered ([@b12-or-42-01-0115]).

Theoretically, exposure of HepG2 cells to borax for either 2 or 24 h may induce alterations in the expression levels in various critical genes, and these genes may therefore serve essential roles in various signaling pathways. The present study explored gene expression alterations directly caused by treatments with doses of borax (4 mM) in HepG2 cells for either 2 or 24 h and investigated the biological functions of those genes with significantly altered expression levels. Analysis of gene expression was performed through assessment of Affymetrix GeneChip data, followed by gene ontology (GO) analysis and pathway analysis.

Materials and methods
=====================

### Cell culture

HepG2 cells were obtained from the China Center for Type Culture Collection (Wuhan University, Wuhan, China) and seeded in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum (FBS; cat. no. 10099-141; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) 1 day prior to borax (4 mM; Tianjin Bodi Chemical Co. Ltd., Tianjin, China) treatment in a humidified 5% CO~2~ incubator at 37°C for either 2 or 24 h. Following 2- or 24-h treatment with 4 mM borax, the culture medium was replenished with fresh media without borax.

### RNA extraction and microarray hybridization

Following borax treatment, total RNA was extracted from HepG2 cells using TRIzol (cat. no. 3101-100; Invitrogen; Thermo Fisher Scientific, Inc.), followed by its purification using a miRNeasy Mini Kit (cat. no. 217004; Qiagen GmbH, Hilden, Germany). RNA integrity was also examined using an Agilent Bioanalyzer 2100 (grant no. G2938A; Agilent Technologies, Inc., Santa Clara, CA, USA). To obtain biotin-tagged cDNA, total RNA was subsequently amplified, labeled and purified using a WT PLUS Reagent kit (cat. no. 902280; Affymetrix; Thermo Fisher Scientific, Inc.). Array hybridization was performed using an Affymetrix GeneChip Human Gene 2.0 ST Array (Affymetrix; Thermo Fisher Scientific, Inc.) and Hybridization Oven 645 (cat. no. 00-0331-220V; Affymetrix; Thermo Fisher Scientific, Inc.), the Gene Chip was subsequently washed using a Hybridization, Wash and Stain Kit (cat. no. 900720; Affymetrix; Thermo Fisher Scientific, Inc.) in a Fluidics Station 450 (cat. no. 00-0079, Affymetrix; Thermo Fisher Scientific, Inc.). A GeneChip Scanner 3000 (cat. no. 00-00213; Affymetrix; Thermo Fisher Scientific, Inc.) was used to scan the results, which were controlled by Command Console Software 4.0 (Affymetrix; Thermo Fisher Scientific, Inc.) to summarize probe cell intensity data, namely, the CEL files with default settings. Following this, CEL files were normalized according to gene and exon level using Expression Console Software 4.0 (Affymetrix; Thermo Fisher Scientific, Inc.). All of the procedures, including array hybridization and scanning, were independently performed according to a standard protocol ([@b20-or-42-01-0115]) for microarray experiments (n=3).

### Validation of selected differentially expressed genes using reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Single-stranded cDNAs were converted from 2.0 µg of total RNA extracted from cells using an RT kit (cat. no. M1701; Promega Corporation, Madison, WI, USA) with a temperature protocol of 72°C for 10 min. qPCR analysis was performed using 2.0 µg cDNA from each sample, pair-specific primers ([Table I](#tI-or-42-01-0115){ref-type="table"}; Shanghai GeneChem Co., Ltd., Shanghai, China) and a SYBR green PCR Master Mix kit (cat. no. 639676; Takara Bio, Inc., Otsu, Japan). The thermocycling conditions used were as follows: 40 cycles at 95°C for 30 sec, 72°C for 45 sec, and 1 cycle at 72°C for 10 min. Quantitative measurement of the expression level of each gene was obtained by independent experiments (n=3). Samples were normalized to the expression level of GAPDH. Additionally, according to the 2^−ΔΔCq^ method ([@b21-or-42-01-0115]), all of the results were detected as fold-change relative to the corresponding mRNA expression level in control cells.

### Construction of adenoviral vectors

PCR was performed to amplify the encoding sequences of abundantly expressed genes. Gene interference RNA fragments (100 µmol; three codon sites; [Table II](#tII-or-42-01-0115){ref-type="table"}) of those amplified sequences were subcloned into a plasmid (300 ng/µl; Shanghai GeneChem Co., Ltd., Shanghai, China) backbone using the T4DNA ligase (cat. no. 170702; Takara Bio, Inc.) following the digestion of the restriction enzyme. The pGCScaspase\--004-iRNA and the GV115-NC were co-transformed into *Escherichia coli* GRM602 with backbone vector GV115-NC for homologous recombination. The recombinant plasmid pAd-iRNA digested with *Pac*I (Fermentas; Thermo Fisher Scientific, Inc.) was used to transfect 293T cells (Thermo Fisher Scientific, Inc.) using Lipofectamine 2000 (cat. no. 11668-027; Invitrogen; Thermo Fisher Scientific, Inc.) for further packaging and amplification of the viruses and used in all groups (including any controls). The time interval was 72 h between transfection and subsequent experimentation. A control group (non-targeting shRNA) and positive control (specific-targeting shRNA) were used.

### Cell culture and transfection

HepG2 cells were seeded in a 96-well black-bottom plate (1,500-2,500 cells/well; Corning Inc., Corning, NY, USA) filled with DMEM supplemented with FBS in a humidified incubator containing 5% CO~2~ at 37°C. The viral particles were added to serum-free medium when confluency reached 20--40 %. The media was replaced with fresh medium supplemented with FBS following 12 h of incubation. Cells were subsequently incubated for a further 72 h until the transfection rate reached 70--90 %. GFP expression was analyzed in HepG2 cells 48 and 72 h post-infection with AdGFP using fluorescence and light microscopy to determine the optimal transfection rate for subsequent experiments. Cells were subsequently collected for further use. Decreased expression of genes following treatment with shRNA was validated with RT-qPCR.

### Cell proliferation assay

To identify the specific effects of those abundantly expressed genes on the proliferation of HepG2 cells, these cells were infected with adenovirus, seeded in a 96-well plate (2×10^3^/well) and cultured in a humidified incubator containing 5% CO~2~ at 37°C for 24 h. The plates were scanned using Celigo Image Cytometer Instrumentation (Nexcelom Bioscience Instruments (Shanghai) Co., Ltd.m Shanghai, China) ([@b22-or-42-01-0115],[@b23-or-42-01-0115]) to acquire images every 24 h, measuring the number of viable cells with 5-day sequential monitoring. Gross quantitative analyses were independently performed (n≥3), including the total number count, cell growth \[shControl/experimental (transfected with RNAiMax) group, \>1.5-fold change\], position information and average integrated intensity of certain gated events for each fluorescence channel in individual wells.

### Statistical analysis

A computational analysis of microarray data was performed using GeneSpring v12.0 (Agilent Technologies, Inc., Santa Clara, CA, USA). Based on a Student\'s t-test analysis, differentially expressed genes were filtered through statistical estimation of fold-changes from replicated samples (fold change ≥2.0) using a P-value threshold (P\<0.05). Distinguishable gene expression of those samples was demonstrated via hierarchical clustering, followed by heatmap generation. Additionally, GO and pathway analyses of differentially expressed genes were performed to determine the potential signaling pathways underlying their biological functions. Public data from bioinformatics resources (<http://www.geneontology.org/>) were utilized for GO enrichment analysis. Ingenuity Pathway Analysis was utilized to identify genes whose expression was changed by at least 2-fold.

Results
=======

### Gene expression changes

Gene microarray analysis revealed that there were significant expressional alterations of 530 genes in HepG2 cells in the 2-h borax treatment group compared with the control group (fold change ≥2.0; P\<0.05). Among them, 146 genes were downregulated and 384 genes were upregulated (P\<0.05; [Fig. 1A](#f1-or-42-01-0115){ref-type="fig"}). Furthermore, the expression levels of 1,763 genes were changed in HepG2 cells when the 24-h borax treatment group was compared with the control group (fold change ≥2.0; P\<0.05). Among these genes, 719 were downregulated and 1,044 were upregulated (P\<0.05; [Fig. 1B](#f1-or-42-01-0115){ref-type="fig"}).

### Gene expression and GO analysis

Differentially expressed genes were stratified by treatment duration and presented as heatmaps either in red (upregulation) or green (downregulation), revealing an overall global change in expression for all genes (P\<0.05; [Fig. 2](#f2-or-42-01-0115){ref-type="fig"}). Furthermore, detectable differences in gene expression patterns among those groups were also revealed by hierarchical clustering analyses. To determine the biological dysfunctionality associated with the altered gene expression induced by borax treatment, public data from bioinformatics resources (<http://www.geneontology.org/>) were utilized for GO enrichment analysis. Based on the cellular components, biological processes and molecular functions of each gene, significantly enriched GO terms were also arranged correspondingly ([Fig. 3](#f3-or-42-01-0115){ref-type="fig"}).

### Pathway analysis

To determine which pathways were involved, Ingenuity Pathway Analysis was utilized to identify genes whose expression was changed by at least 2-fold. Furthermore, analyses of functional pathways indicated that the genes with expression levels that were significantly altered in cells from the 2-h treatment group compared with those in the control group were involved in seven KEGG pathways (P\<0.01; [Table III](#tIII-or-42-01-0115){ref-type="table"}). Furthermore, significantly altered genes in cells from the 24-h treatment group compared with those in the control group were primarily associated with five KEGG pathways (P\<0.01; [Table IV](#tIV-or-42-01-0115){ref-type="table"}).

### Validation of the expression of genes by qPCR

To validate potentially valuable genes that were screened by microarray results, the results between the clustered selected transcripts and those from RT-qPCR were compared ([Fig. 2](#f2-or-42-01-0115){ref-type="fig"}). Following borax treatment, 26 downregulated genes were identified on the basis of fold-change threshold, and the potentially functional correlation of caspase\--6 or P53 signaling with proliferation in HepG2 cells was suggested. Additionally, RT-qPCR also revealed a few abundantly expressed genes, including AZI2, BPGM, FBXO9, MBTPS1, NBPF1, PRUNE1, SNX13, SETD5, TSR2, TTLL4, UPF2, RCN2, USP16, PPcaspase-1, MTIF2, MAPK4, LMAN2L, CENPN, CDCA8 and PPIP5K2, in HepG2 cells with no borax treatment.

### Effects of abundantly expressed genes on cell proliferation

HepG2 cells infected with recombinant adenovirus were cultured for 48--72 h. When adenoviral green fluorescent protein (AdGFP) reached over 80%, recombinant adenovirus was considered to be efficiently infected HepG2 cells *in vitro* ([Fig. 4](#f4-or-42-01-0115){ref-type="fig"}), and decreased expression of genes was established following transfection with each shRNA ([Fig. 5](#f5-or-42-01-0115){ref-type="fig"}). On the 5th day following the infection, the proliferation of iRNA-treated HepG2 cells was significantly suppressed (fold change ≥1.5) compared with those in the control group (P\<0.05). Furthermore, the target genes of RNAi fragments included PRUNE1, NBPF1, PPcaspase-1, UPF2 and MBTPS1 (fold change ≥1.50; [Fig. 6](#f6-or-42-01-0115){ref-type="fig"}). These findings indicted that, compared with control group cells, cell proliferation in the shRNA group was significantly reduced (fold change ≥1.5). Therefore it was inferred that the target gene of RNA lentivirus in the shRNA group was tumor cells proliferation-related positive gene.

Discussion
==========

Boron is a naturally abundant element on the earth ([@b24-or-42-01-0115]). Notably, borax is a boron compound, which plays essential roles in many industries and in daily life ([@b25-or-42-01-0115]). Currently, several boron-containing molecules have been applied for the treatment of multiple diseases, including inflammation, diabetes and cancer ([@b26-or-42-01-0115],[@b27-or-42-01-0115]). Some of these treatments have produced positive results in preclinical and clinical trials ([@b28-or-42-01-0115],[@b29-or-42-01-0115]). For instance, previous studies revealed boric acid/borax mediated protection against TiO~2~ genotoxicity in peripheral blood cells ([@b30-or-42-01-0115]). In addition, borax mediated the stimulation of sister chromatid exchange in human chromosomes and/or lymphocyte proliferation ([@b1-or-42-01-0115]). Furthermore, a previous study revealed that peripheral blood cells with aflatoxin B1-induced genetic damage were sufficiently rescued by borax treatment, which has also been indicated to be an effective antiepileptic drug ([@b31-or-42-01-0115],[@b32-or-42-01-0115]).

The properties of borax are also considered to be correlated with genetic defects and genotoxicity. Specifically, it is widely accepted that when borax is applied at high concentrations, it is cytotoxic to mammalian cells, although cell transformation assays show that borax treatment is weakly mutagenic and not oncogenic ([@b33-or-42-01-0115]). In our previous study, it was indicated that borax induced a strong increase in caspase\--6 production, which was accompanied by the enhanced expression of p53-modulated genes, including p21, Bax and Puma ([@b16-or-42-01-0115]). Considering that the precise regulation of borax-induced genotoxicity has not been well defined, novel mechanisms underlying the genetic actions and potential new biological effects of borax on various cell-types require more insight.

In the present study, microarray analysis indicated that the expression levels of 530 genes were changed in HepG2 cells in the 2-h treatment group. Among them, 146 were downregulated and 384 were upregulated. Notably, MYO10, one of the downregulated genes, encodes a member of the myosin superfamily, which mediates the migration and invasion of tumor cells, suggesting that it contributes to the metastatic phenotype, possibly via its direct involvement in the assembly of molecular motors ([@b34-or-42-01-0115],[@b35-or-42-01-0115]). miR-4521 was also downregulated, which is closely correlated with signal transduction, mediating DNA binding, receptor activity and other processes ([@b36-or-42-01-0115]). The DDIT3 gene, which encodes a suppressor protein that primarily inhibits mTOR signaling under stress conditions and is partially involved in cancer progression ([@b37-or-42-01-0115]), was also downregulated with borax treatment. Heat shock protein (HSP)25 protein is encoded by the HSPβ-1 gene. HSPβ-1 is a member of the HSP family ([@b38-or-42-01-0115]) and is abundantly expressed in various types of cancer associated with poor prognosis and resistance to chemotherapy, possibly through their aggressive tumor behavior and metastasis ([@b39-or-42-01-0115]). In the present study, HSPβ-1 was also significantly downregulated. Early growth response protein 1, which is involved in the initial stage of the inflammatory response, possibly through its critical roles as a tumor suppressor or promoter ([@b40-or-42-01-0115]), was upregulated following 2-h borax treatment in the present study. Furthermore, prostaglandin-endoperoxide synthase 2, a principal inflammatory mediator and a UV-inducible enzyme the catalyzes the first step in the synthesis of prostaglandin E2 ([@b41-or-42-01-0115]), was also upregulated. Additionally, TNFAIP3 and caspase\--6, which are associated with inflammation and stress reaction ([@b42-or-42-01-0115]), were also found to be upregulated. Notably, TNFAIP3 acts as a critical molecular switch to discriminate tumor necrosis factor-induced NF-κB signaling from the activated JNK signaling pathways in hepatocytes when stimulated with varying cytokine concentrations under normal or pathological conditions ([@b43-or-42-01-0115]). These findings implicate downregulated/upregulated genes following borax treatment impact the migration and invasion of tumor cells, DNA binding signal transduction, inflammation and stress reactions. However, the specific mechanisms involved require further study.

The expression levels of 1,763 genes were changed in cells from the 24-h treatment group compared with those in the control group. Specifically, 719 genes were downregulated and 1,044 genes were upregulated ([Fig. 1](#f1-or-42-01-0115){ref-type="fig"}). Among them, the downregulated genes included B3GALT6, a critical enzyme catalyzing the formation of the tetrasaccharide linkage region, the mutation of which results in proteoglycan maturation defects ([@b44-or-42-01-0115]). In the present study, FAM20B was downregulated in the 24-h treatment group. Notably, it was previously indicated that FAM20B deletion is associated with Ehlers-Danlos syndrome ([@b45-or-42-01-0115],[@b46-or-42-01-0115]). UBE4B was also downregulated in cells from the 24-h treatment group in the present study. A previous study revealed that silencing of UBE4B expression inhibited the proliferation, colony formation, migration and invasion of liver cancer cells *in vitro*, and resulted in significant apoptosis. Therefore, it was suggested that this gene may be a good prognostic candidate for liver cancer ([@b47-or-42-01-0115]). The overexpression of UBE4B, which is widely accepted as a p53 upstream target gene, contributes to the migration and invasion of tumor cells ([@b48-or-42-01-0115],[@b49-or-42-01-0115]). UBIAD1, also known as UbiA prenyltransferase domain-containing protein 1, functions as an important regulator in the cell progression of bladder and prostate cancer, as well as vascular integrity, possibly through its modulation of metabolism of intracellular cholesterol and protection against oxidative stress ([@b50-or-42-01-0115]). UBIAD1 was also downregulated. Additionally, PLOD1, which is associated with cell apoptosis, cell cycle and metastasis ([@b51-or-42-01-0115]), was also found to be downregulated.

In the present study, 24-h treatment with borax upregulated the expression of several genes, including ZNF84, which is also known as a zinc finger transcription factor gene ([@b52-or-42-01-0115]). ZNF84 is located in chromosome 12q24.33, which is correlated with recurrent breakpoints and allelic loss in a few types of cancer ([@b52-or-42-01-0115],[@b53-or-42-01-0115]). Immediate early response 3 was another upregulated gene that normally regulates apoptosis, proliferation and the maintenance of HCCs ([@b54-or-42-01-0115],[@b55-or-42-01-0115]). TCF19, which was also upregulated, has been identified to be a good prognostic candidate for HCC, thereby becoming a promising candidate for preclinical and/or clinical studies to determine its potential risk in HCCs ([@b56-or-42-01-0115]).

Distinct sets of genes were found to be altered after different treatment durations, namely, borax treatments for either 2 or 24 h in HepG2 cells. Exposure to borax for 2 h altered the expression levels of genes encoding proteins involved in signal transduction underlying stress response, biopolymer metabolic process, the inflammatory response (e.g., NF-κB and caspase\--6) and unfolded protein response among other possibilities. Notably, the results for cells from the 2-h treatment group revealed the disruption of certain metabolic processes involved in inflammation and stress response. Accordingly, borax treatment for 24 h caused the dysregulation of genes involved in a number of signaling pathways, which are associated with enhanced cell proliferation and apoptosis underlying the disruption of both vascular integrity and suppression of tumor cell progression ([@b16-or-42-01-0115]), indicating that the disruption of those signaling pathways may contribute to carcinogenesis in borax-treated HepG2 cells.

Enriched GO analyses in the present study revealed that the significantly enriched gene sets included the response to primary metabolic process, response to stimulus, biosynthetic process, developmental process, apoptotic process, immune system process, binding, catalytic activity, cell part, organelles, and others. In the present study, the downregulation of PRUNE1, NBPF1, PPcaspase-1, UPF2, and MBTPS1 suggested that they inhibited the growth of HepG2 cells. For instance, PRUNE1 is a member of the Asp-His-His phosphoesterase protein superfamily, which is involved in cell motility and is implicated in cancer progression ([@b57-or-42-01-0115]). NBPF1 is a tumor suppressor in several cancer types and can act as a tumor suppressor modulating cell apoptosis, possibly through the inhibition of various proteins involved in the cell cycle ([@b58-or-42-01-0115]). NBPF1 is also implicated in cancer progression ([@b59-or-42-01-0115]). PPcaspase-1 has also been reported to be upregulated in human colon cancer cells. Accordingly, small interfering RNA-mediated PPcaspase-1 knockdown resulted in cell apoptosis in those cells ([@b60-or-42-01-0115]). Therefore, precise modulations of the expression level of these critical genes leads to accurate regulation of cellular activity, thereby contributing to the suppressed initiation of cancer progression. Notably, future progress in identifying the basic features of these essential proteins may provide further insights into the diagnosis and prognosis of certain types of human cancer and may also aid the production of novel strategies to develop more effective and efficient therapeutic agents against those types of cancer.

To conclude, 2- and 24-h borax treatment caused significant alterations in the expression levels of various genes. However, based on the length of treatment different sets of genes were altered. Dysregulated genes were identified to be involved in various critical signaling pathways underlying biological processes, including the inflammatory response, stress response, cell apoptosis, signal transduction and cell-to-cell signaling. Some of these changes in those biological processes persisted 24 h after treatment. Thus, it was demonstrated that borax could induce significant alterations in gene expression. However, further studies are required to determine whether these changes are ascribed to genetic alterations in the promoter or regulatory regions of dysregulated genes. Notably, these studies could bring further insights into how borax affects gene expression. The present study provides the fundamental basis for exploring the carcinogenicity of borax treatment in HepG2 to reveal the underlying cellular and molecular mechanisms, the basic biological characteristics and associated pathways, which warrant further investigation.
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![Upregulated and downregulated genes following treatment with 4 mM borax in HepG2 cells after 2 and 24 h were determined using gene microarray analysis (2 and 24 h groups vs. control group, P\<0.05), respectively (over 2-fold change).](OR-42-01-0115-g00){#f1-or-42-01-0115}

![Heatmaps of differentially expressed genes due to borax treatments in HepG2 cells for 2 and 24 h (\>2-fold change, P\<0.05). Red indicates upregulation whereas green indicates downregulation of gene expression relative to control (untreated cells).](OR-42-01-0115-g01){#f2-or-42-01-0115}

![Enriched GO terms according to biological processes, molecular functions, and cellular components. GO terms are ordered by enrichment score with the highest enriched term at the bottom of the list. Differentially expressed transcripts involved in the term (count) P\<0.05 with and fold change \>2.0 were included. GO, gene ontology.](OR-42-01-0115-g02){#f3-or-42-01-0115}

![Efficiency of adenovirus infection in HepG2 cells. GFP expression was analyzed in HepG2 cells 48 and 72 h post-infection with AdGFP using fluorescence (lower panels) and light (phase-contrast; upper panels) microscopy (magnification, ×100) to determine the optimal transfection rate for subsequent experiments. (A) (48 h) 40% and (B) (72 h) 80% of cells exhibited GFP expression, respectively. AdGFP, adenoviral green fluorescent protein.](OR-42-01-0115-g03){#f4-or-42-01-0115}

![The decreased expression of genes was established following transfection with each shRNA with real-time PCR. \*P\<0.05, vs. shControl. shRNA, short hairpin RNA.](OR-42-01-0115-g04){#f5-or-42-01-0115}

###### 

HepG2 cells were transfected with RNAiMax and counts of live adherent HepG2 in cell culture using a Celigo cytometer at the time points indicated. (A) GFP expression of cells infected with different AdGFP-iRNA. (B) Graphs indicated the number of viable cells. (C) Graphs indicated cell growth according to fold change \[fold change=shControl/experimental group (transfected with RNAiMax) ≥1.5, P\<0.05\]. Ctrl, non-targeting shRNA, PC, positive control (specific-targeting shRNA); AdGFP, adenoviral green fluorescent protein.
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###### 

Sequences of primers employed for reverse transcription-quantitative polymerase chain reaction and their anticipated polymerase chain reaction product size.

  Primer     Forward (5′-3′)           Reverse (5′-3′)           Length (bp)
  ---------- ------------------------- ------------------------- -------------
  AZI2       AACACTAAGGAATCGAAACTCG    GAGCAAAATGGGAAGCAACAG     186
  BPGM       GCGTCTAAATGAGCGTCACTAT    GGAGGCGGGGTTACATTGTAG     120
  FAM102B    TGCTGGTGAATCTGAATCTTTG    CTGAGGTATTTCTCCTGTGGC     236
  FBXO9      AGTGGATGTTTGAACTTGCTC     GCCTGTTCTTGTTTTCCTTTG     121
  HOXB5      GACCACGATCCACAAATCAAGC    TGCCACTGCCATAATTTAGCAAC   120
  KIAA0430   ACCCTCCACTTCGCCAATG       CTTTGCGAGTCTAACAGTGCG     96
  MBTPS1     TTTGACACTGGGCTGAGCGAGAA   CGCCGATGCTGAGGTTTAACACG   280
  MYO10      AGGAGGAAGTTCGGGAAGTGT     CTTCTCCCCTGAGGAACATTG     192
  NBPF1      GCCCTGATGTAGAAACTTC       ATTCTTAGCAGTACGATTCG      146
  PRUNE1     GCCTCAAGTACCCACCCTAAC     AGAGGGCACTCATCCACCAAG     278
  SETD5      TACCTGGTGTCCTTGTGGTCT     CGCTTCTTGGGTTTGGTTCTT     246
  SNX13      ATATCCTCTGCTTTGTGGGTG     AGATTCATCATCGCTTAGTGT     281
  TSR2       CCCTGTTCCTCTGTCTGGCTCC    CTTCCTCACAATGACCGCACC     169
  TTLL4      TCTTTCTGCTTGCGTTCGAG      AGAGGTATGGTTCTGTGGATGAG   154
  UPF2       GGAGGTATCAAGTCCCGATGA     GTTGGGTAACTGCTGTAGGAAAG   202
  RCN2       TTCAGGTCCCGGTTTGAGTCT     TCAAGCCTGCCATCGTTATCT     252
  USP16      ATGAGGTCCAGTATTGTAGTTC    ACTGAGTCCTTTCACGGTTAT     236
  RASL11A    TATTCACGGCTGGTCTATGTCG    CACGCATTTGGACAGGGAATC     120
  PPIL1      TGGGAATCATTGTGCTGGAG      CGAGGGTCACAAAGAACTGG      291
  MTIF2      TGGTTGCTGGAAAATGTTGGG     CACGGGCTTTCTGATGTGCTT     276
  MAPK4      CGGTGTCAATGGTTTGGTGC      GACGATGTTGTCGTGGTCCA      151
  LMAN2L     ACTCGCTGTCGAAGCCCTA       CTGGGGTAAGGCGGATATACT     105
  CENPN      TGAACTGACAACAATCCTGAAG    CTTGCACGCTTTTCCTCACAC     129
  CDCA8      GCAGGAGAGCGGATTTACAAC     CTGGGCAATACTGTGCCTCTG     141
  EFR3A      GCTGTTCCGCTTTGCGTCCTC     AGAAGTTGGTCCAGTGCCTCC     232
  PPIP5K2    ACTGGACAAAGCGGTTGCCTAT    TGGGATTATTTGGGTCACGGT     167

###### 

Sequences of RNAis (three codon sites for each gene) employed to plasmid backbone.

  Genes     Codon sites   Target sequence
  --------- ------------- -----------------------
  PRUNE1    PSC56272      TCGAGAAGTGCAGTCAGAT
            PSC56273      ATGTAAGTTGCCAACAGTT
            PSC56274      GCATGGATCTTGAACAGAA
  NBPF1     PSC29636      GCGAGAAGGCAGAGACGAA
            PSC29637      TGACAATGATCACGATGAA
            PSC29638      AGTCATATTCCCACAGTAA
  PPIL1     PSC40511      ACAGAATTATCAAAGACTT
            PSC40512      AGGTTACTACAATGGCACA
            PSC40513      CTCCAAAGACCTGTAAGAA
  UPF2      PSC56248      GCCTAGATTCGAGCTTAAA
            PSC56249      CACCTAATGCAGATCTAAT
            PSC56250      CTTGTACCAAGGAAAGTAA
  MBTPS1    PSC56266      GTCGTGATAACACAGACTT
            PSC56267      TAACAATGTAATCATGGTT
            PSC56268      TGACTTTGAAGGTGGAATT
  SETD5     PSC56263      ACTTTGTAAGTCAGATGAT
            PSC56264      GCATTTAGATCATCACAAA
            PSC56265      ATCAGGAACACTGACCATT
  RCN2      PSC42354      GCTTCATCTAATTGATGAA
            PSC42355      GGTTTGAGTCTTGAAGAAT
            PSC42356      GATGTATGATCGTGTGATT
  TSR2      PSC48385      CCAGTTTGTTAAACTCCTT
            PSC48386      CTTTACTCAGGATTTACTA
            PSC48387      AAAGAATGTGCGGTCTTTA
  SNX13     PSC56275      CAATTCAATGAGGAATGTT
            PSC56276      CTGAAATCTTTGATGACAT
            PSC56277      TGATTCTAACTGCAACTAT
  CENPN     PSC32095      AACTGACAACAATCCTGAA
            PSC32096      AATGCAGTCTGGATTCGAA
            PSC32097      TAGTTCAGCACTTGATCCA
  PPIP5K2   PSC36126      CTGTGATGTGTTTCAGCAT
            PSC36127      TGAAATTTCCACTAGCGAA
            PSC36128      AGAGATTCATTGGAGACTA
  USP16     PSC56254      GTGATATTCCACAAGATTT
            PSC56255      GAATAAACTGCTTTGTGAA
            PSC56256      CAGAAGAAATCATGTTTAT
  TTLL4     PSC42339      TGGTCAGTTTGAACGAATT
            PSC42340      ACATGAAGTCTCCTAGTTT
            PSC42341      CCTCATCTACAGTCTCTTT
  AZI2      PSC56260      ATATCGAGAGGTTTGCATT
            PSC56261      GAGGACAGAGGTGGAAACTCA
            PSC56262      CAGCTACAATCTAAAGAAGTA
  LMAN2L    PSC41153      CATAGTCATTGGTATCATA
            PSC41154      GGCATTTGACGATAATGAT
            PSC41155      AACGTTCGAGTACTTGAAA
  CDCA8     PSC24168      TTGACTCAAGGGTCTTCAA
            PSC24169      TGGATATCACCGAAATAAA
            PSC24170      CCTCCTTTCTGAAAGACTT
  BPGM      PSC39388      AGCCATTAAGAAAGTAGAA
            PSC39389      CATTCTTCTGGAATTGGAT
            PSC39390      CGAAGTATTACGTGGCAAA
  MTIF2     PSC56269      AGACTCACATTTAGATGAA
            PSC56270      CGTAATGGACATGTAATTT
            PSC56271      AGGAGAAGAAATTCTTGAA
  MAPK4     PSC56251      AAGGATCGTGGATCAACAT
            PSC56252      GACCTCAATGGTGCGTGCA
            PSC56253      TCGCGCAGTGGGTCAAGAG
  FBXO9     PSC56257      AGAGGTTCAACAAACTCAT
            PSC56258      TCAGATCATTGGAGCAGTT
            PSC56259      TGATATAGAGTTCAAGATT

###### 

Differentially expressed genes involved in signal transduction (2 h vs. Control group).

  Pathway/genebank ID                                    Probe_Set_ID      Gene symbol   Description of expression product                                                               Fold change   P-values   Regulation after borax treeatment
  ------------------------------------------------------ ----------------- ------------- ----------------------------------------------------------------------------------------------- ------------- ---------- -----------------------------------
  hsa04010:MAPK signaling pathway                                                                                                                                                                                 
                                                                                                                                                                                                                  
  NM_001202233                                           TC12000414.hg.1   NR4A1         Nuclear receptor subfamily 4, group A, member 1                                                 21.7          0.000881   Up
  NM_005252                                              TC11001948.hg.1   FOS           FBJ murine osteosarcoma viral oncogene homolog                                                  11.3          0.000164   Up
  NM_001199741                                           TC01000745.hg.1   GADD45A       Growth arrest and DNA-damage-inducible, alpha                                                   10.7          0.000054   Up
  NM_004419                                              TC10000801.hg.1   DUSP5         Dual specificity phosphatase 5                                                                  10.6          0.000096   Up
  NM_000575                                              TC02002218.hg.1   IL1A          Interleukin-1, alpha                                                                            8.3           0.005040   Up
  NM_001394                                              TC08001099.hg.1   DUSP4         Dual specificity phosphatase 4                                                                  5.6           0.002509   Up
  NM_005354                                              TC19001285.hg.1   JUND          Jun D proto-oncogene                                                                            3.4           0.001100   Up
  NM_015675                                              TC19000055.hg.1   GADD45B       Growth arrest and DNA-damage-inducible, beta                                                    3.3           0.000382   Up
  NM_001195053                                           TC12001625.hg.1   DDIT3         DNA-damage-inducible transcript 3                                                               2.3           0.005761   Up
  NM_030640                                              TC12001255.hg.1   DUSP16        Dual specificity phosphatase 16                                                                 2.3           0.000079   Up
  NM_000576                                              TC02002219.hg.1   IL1B          Interleukin-1, beta                                                                             2.1           0.016505   Up
  NM_004651                                              TC05001184.hg.1   MYO10         Myosin 10                                                                                       −7.17         0.001269   Down
  NM_005345                                              TC06000384.hg.1   HSPA1A        Heat shock 70 kDa protein 1A                                                                    −4.2          0.011012   Down
  NM_005346                                              TC06000385.hg.1   HSPA1B        Heat shock 70 kDa protein 1B                                                                    −4.3          0.010610   Down
  NM_002228                                              TC01001927.hg.1   JUN           Jun proto-oncogene                                                                              −2.1          0.000287   Down
                                                                                                                                                                                                                  
  hsa04064:NF-kappa B signaling pathway                                                                                                                                                                           
                                                                                                                                                                                                                  
  NM_000963                                              TC01003638.hg.1   PTGS2         Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)           75.7          0.000000   Up
  NM_006290                                              TC06001027.hg.1   TNFAIP3       Tumor necrosis factor, alpha-induced protein 3                                                  68.3          0.000000   Up
  NM_020529                                              TC14001036.hg.1   NFKBIA        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha             9.2           0.000014   Up
  NM_001165                                              TC11000956.hg.1   BIRC3         Baculoviral IAP repeat containing 3                                                             3.7           0.000004   Up
  NM_002089                                              TC04001286.hg.1   CXCL2         Chemokine (C-X-C motif) ligand 2                                                                4.0           0.010873   Up
  NM_015675                                              TC19000055.hg.1   GADD45B       Growth arrest and DNA-damage-inducible, beta                                                    3.3           0.000382   Up
  NM_000576                                              TC02002219.hg.1   IL1B          Interleukin-1, beta                                                                             2.1           0.016505   Up
                                                                                                                                                                                                                  
  hsa04621:NOD-like receptor signaling pathway                                                                                                                                                                    
                                                                                                                                                                                                                  
  NM_006290                                              TC06001027.hg.1   TNFAIP3       Tumor necrosis factor, alpha-induced protein 3                                                  68.3          0.000000   Up
  NM_020529                                              TC14001036.hg.1   NFKBIA        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha             9.2           0.000014   Up
  NM_002089                                              TC04001286.hg.1   CXCL2         Chemokine (C-X-C motif) ligand 2                                                                4.0           0.010873   Up
  NM_001165                                              TC11000956.hg.1   BIRC3         Baculoviral IAP repeat containing 3                                                             3.7           0.000004   Up
  NM_000576                                              TC02002219.hg.1   IL1B          Interleukin-1, beta                                                                             2.1           0.016505   Up
  NM_000600                                              TC05002383.hg.1   IL6           Interleukin-6                                                                                   2.4           0.007231   Up
  NM_100616406                                           TC17000132.hg.1   MIR4521       MicroRNA 4521                                                                                   −6.61         0.000125   Down
                                                                                                                                                                                                                  
  hsa04115:p53 signaling pathway                                                                                                                                                                                  
                                                                                                                                                                                                                  
  NM_001199741                                           TC01000745.hg.1   GADD45A       Growth arrest and DNA-damage-inducible, alpha                                                   10.7          0.000054   Up
  NM_003246                                              TC15000270.hg.1   THBS1         Thrombospondin 1                                                                                6.5           0.002300   Up
  NM_000602                                              TC07000643.hg.1   SERPINE1      Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   4.7           0.010348   Up
  NM_021127                                              TC18000213.hg.1   PMAIP1        Phorbol-12-myristate-13-acetate-induced protein 1                                               4.7           0.000034   Up
  NM_015675                                              TC19000055.hg.1   GADD45B       Growth arrest and DNA-damage-inducible, beta                                                    3.3           0.000382   Up
                                                                                                                                                                                                                  
  hsa04141:Protein processing in endoplasmic reticulum                                                                                                                                                            
                                                                                                                                                                                                                  
  NM_014330                                              TC19000711.hg.1   PPP1R15A      Protein phosphatase 1, regulatory subunit 15A                                                   4.4           0.006746   Up
  NM_018566                                              TC01003773.hg.1   YOD1          YOD1 OTU deubiquinating enzyme 1 homolog                                                        3.7           0.000181   Up
  NM_001433                                              TC17001796.hg.1   ERN1          Endoplasmic reticulum to nucleus signaling 1                                                    2.6           0.000008   Up
  NM_001195053                                           TC12001625.hg.1   DDIT3         DNA-damage-inducible transcript 3                                                               2.3           0.005761   Up
  NM_005346                                              TC06000385.hg.1   HSPA1B        Heat shock 70 kDa protein 1B                                                                    −4.3          0.010610   Down
  NM_005345                                              TC06000384.hg.1   HSPA1A        Heat shock 70 kDa protein 1A                                                                    −4.2          0.011012   Down
  NM_003791                                              TC16001307.hg.1   MBTPS1        Membrane-bound transcription factor peptidase, site 1                                           −3.2          0.000643   Down
  NM_001172415                                           TC09001009.hg.1   BAG1          BCL2-associated athanogene                                                                      −2.1          0.000440   Down
                                                                                                                                                                                                                  
  hsa04668:TNF signaling pathway                                                                                                                                                                                  
                                                                                                                                                                                                                  
  NM_000963                                              TC01003638.hg.1   PTGS2         Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)           75.7          0.000000   Up
  NM_006290                                              TC06001027.hg.1   TNFAIP3       Tumor necrosis factor, alpha-induced protein 3                                                  68.3          0.000000   Up
  NM_001168319                                           TC06000087.hg.1   EDN1          Endothelin 1                                                                                    13.1          0.000004   Up
  NM_005252                                              TC11001948.hg.1   FOS           FBJ murine osteosarcoma viral oncogene homolog                                                  11.3          0.000164   Up
  NM_020529                                              TC14001036.hg.1   NFKBIA        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha             9.2           0.000014   Up
  NM_002089                                              TC04001286.hg.1   CXCL2         Chemokine (C-X-C motif) ligand 2                                                                4.0           0.010873   Up
  NM_001165                                              TC11000956.hg.1   BIRC3         Baculoviral IAP repeat containing 3                                                             3.7           0.000004   Up
  NM_001130046                                           TC02001364.hg.1   CCL20         Chemokine (C-C motif) ligand 20                                                                 3.0           0.002008   Up
  NM_000600                                              TC05002383.hg.1   IL6           Interleukin-6                                                                                   2.4           0.007231   Up
  NM_000576                                              TC02002219.hg.1   IL1B          Interleukin-1, beta                                                                             2.1           0.016505   Up
  NM_003955                                              TC17001917.hg.1   SOCS3         Suppressor of cytokine signaling 3                                                              2.1           0.003726   Up
  NM_002228                                              TC01001927.hg.1   JUN           Jun proto-oncogene                                                                              −2.1          0.000287   Down
                                                                                                                                                                                                                  
  hsa04620:Toll-like receptor signaling pathway                                                                                                                                                                   
                                                                                                                                                                                                                  
  NM_005252                                              TC11001948.hg.1   FOS           FBJ murine osteosarcoma viral oncogene homolog                                                  11.3          0.000164   Up
  NM_020529                                              TC14001036.hg.1   NFKBIA        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha             9.2           0.000014   Up
  NM_000600                                              TC05002383.hg.1   IL6           Interleukin-6                                                                                   2.4           0.007231   Up
  NM_000576                                              TC02002219.hg.1   IL1B          Interleukin-1, beta (IL1B)                                                                      2.1           0.016505   Up
  NM_002228                                              TC01001927.hg.1   JUN           Jun proto-oncogene                                                                              −2.1          0.000287   Down

###### 

Differentially expressed genes involved in signal transduction (24 h vs. control group).

  Pathway/Genebank ID                            Probe_Set_ID      Gene symbol   Description of expression product                                                               Fold change   P-values   Regulation after borax treeatment
  ---------------------------------------------- ----------------- ------------- ----------------------------------------------------------------------------------------------- ------------- ---------- -----------------------------------
  hsa04110:Cell cycle                                                                                                                                                                                     
                                                                                                                                                                                                          
  NM_002392                                      TC12000606.hg.1   MDM2          Mdm2, p53 E3 ubiquitin protein ligase homolog                                                   13.8          0.00010    Up
  NM_001199741                                   TC01000745.hg.1   GADD45A       Growth arrest and DNA-damage-inducible, alpha                                                   7.9           0.00006    Up
  NM_000389                                      TC06000532.hg.1   CDKN1A        Cyclin-dependent kinase inhibitor 1A (p21, Cip1)                                                4.4           0.00015    Up
  NM_001259                                      TC07001603.hg.1   CDK6          Cyclin-dependent kinase 6                                                                       4.3           0.00013    Up
  NM_001079846                                   TC16000823.hg.1   CREBBP        CREB binding protein (CREBBP)                                                                   3.0           0.00007    Up
  NM_001799                                      TC05000301.hg.1   CDK7          Cyclin-dependent kinase 7                                                                       2.8           0.00039    Up
  NM_007637                                      TC10001228.hg.1   ZNF84         Zinc finger protein 84                                                                          2.42          0.00063    Up
  NM_001789                                      TC03001374.hg.1   CDC25A        Cell division cycle 25 homolog A                                                                2.4           0.00041    Up
  NM_002553                                      TC07001724.hg.1   ORC5          Origin recognition complex, subunit 5                                                           2.3           0.00012    Up
  BC012827                                       TC01000545.hg.1   CDC20         Cell division cycle 20 homolog                                                                  2.2           0.00364    Up
  NM126792                                       TC05001184.hg.1   B3GALT6       Beta 1,3-galactosyltransferase polypeptide 6                                                    −18.97        0.00000    Down
  NM009917                                       TC06001313.hg.1   FAM20B        Family with sequence similarity 20, member B                                                    −5.13         0.00002    Down
  NM_001262                                      TC01000619.hg.1   CDKN2C        Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)                                       −4.8          0.00364    Down
  NM_003318                                      TC06000761.hg.1   TTK           TTK protein kinase                                                                              −3.7          0.00008    Down
  NM_001237                                      TC04001516.hg.1   CCNA2         Cyclin A2 (CCNA2)                                                                               −3.5          0.00007    Down
  NM_004701                                      TC15000449.hg.1   CCNB2         Cyclin B2 (CCNB2)                                                                               −2.7          0.00011    Down
  NM_005611                                      TC16000448.hg.1   RBL2          Retinoblastoma-like 2 (p130)                                                                    −2.6          0.00001    Down
  NM_001178138                                   TC03001849.hg.1   TFDP2         Transcription factor Dp-2 (E2F dimerization partner 2)                                          −2.5          0.00001    Down
  NM_001786                                      TC02001182.hg.1   CDK1          Cyclin-dependent kinase 1                                                                       −2.5          0.00163    Down
  NM_002388                                      TC06001799.hg.1   MCM3          Minichromosome maintenance complex component 3                                                  −2.5          0.00000    Down
  NM_057749                                      TC08001438.hg.1   CCNE2         Cyclin E2 (CCNE2)                                                                               −2.4          0.00622    Down
  NM_001042749                                   TC0X000606.hg.1   STAG2         Stromal antigen 2 (STAG2                                                                        −2.2          0.00017    Down
  NM_005915                                      TC02002376.hg.1   MCM6          Minichromosome maintenance complex component 6                                                  −2.1          0.00019    Down
  NM_001136197                                   TC19000070.hg.1   FZR1          Fizzy/cell division cycle 20 related 1                                                          −2.1          0.00348    Down
  NM_022809                                      TC05001829.hg.1   CDC25C        Cell division cycle 25 homolog C                                                                −2.1          0.00092    Down
                                                                                                                                                                                                          
  hsa04115:p53 signaling pathway                                                                                                                                                                          
                                                                                                                                                                                                          
  NM_002392                                      TC12000606.hg.1   MDM2          Mdm2, p53 E3 ubiquitin protein ligase homolog                                                   13.8          0.00010    Up
  NM_008870                                      TC13000386.hg.1   IER3          Immediate early response 3                                                                      8.47          0.00200    Up
  NM_001199741                                   TC01000745.hg.1   GADD45A       Growth arrest and DNA-damage-inducible, alpha                                                   7.9           0.00006    Up
  NM_021127                                      TC18000213.hg.1   PMAIP1        Phorbol-12-myristate-13-acetate-induced protein 1                                               6.1           0.00001    Up
  NM_000389                                      TC06000532.hg.1   CDKN1A        Cyclin-dependent kinase inhibitor 1A                                                            4.4           0.00015    Up
  NM_001259                                      TC07001603.hg.1   CDK6          Cyclin-dependent kinase 6                                                                       4.3           0.00013    Up
  NM_001172477                                   TC08001496.hg.1   RRM2B         Ribonucleotide reductase M2 B                                                                   3.7           0.00015    Up
  NM_001199933                                   TC06001997.hg.1   SESN1         Sestrin 1                                                                                       3.6           0.00004    Up
  NM_000602                                      TC07000643.hg.1   SERPINE1      serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   2.2           0.00406    Up
  NM_004324                                      TC19000716.hg.1   BAX           BCL2-associated X protein                                                                       2.2           0.00672    Up
  NM_001034                                      TC02000057.hg.1   RRM2          ribonucleotide reductase M2                                                                     −2.9          0.00010    Down
  NM_002639                                      TC18000226.hg.1   SERPINB5      Serpin peptidase inhibitor, clade B (ovalbumin), member 5                                       −2.8          0.00756    Down
  NM_001196                                      TC01000866.hg.1   BID           BH3 interacting domain death agonist                                                            −2.5          0.00002    Down
  NM_016426                                      TC22000394.hg.1   GTSE1         G-2 and S-phase expressed 1                                                                     −2.4          0.00019    Down
  NM_003620                                      TC17000739.hg.1   PPM1D         Protein phosphatase, Mg2+/Mn2+ dependent, 1D                                                    4.5           0.00005    Up
  NM_003842                                      TC08001049.hg.1   TNFRSF10B     Tumor necrosis factor receptor superfamily, member 10b                                          3.8           0.00005    Up
  NM_031459                                      TC01000377.hg.1   SESN2         Sestrin 2                                                                                       3.7           0.00119    Up
  NM_003246                                      TC15000270.hg.1   THBS1         Thrombospondin 1                                                                                2.5           0.00013    Up
  NM_010277                                      TC66000070.hg.1   UBE4B         Ubiquitination factor E4B                                                                       −17.44        0.00000    Down
  NM_005351                                      TC62000079.hg.1   PLOD1         Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1                                              −16.78        0.00104    Down
  NM_004701                                      TC15000449.hg.1   CCNB2         Cyclin B2                                                                                       −2.7          0.00011    Down
  NM_001786                                      TC02001182.hg.1   CDK1          Cyclin-dependent kinase 1                                                                       −2.5          0.00163    Down
  NM_057749                                      TC08001438.hg.1   CCNE2         Cyclin E2                                                                                       −2.4          0.00622    Down
  NM_022470                                      TC03002022.hg.1   ZMAT3         Zinc finger, matrin-type 3                                                                      −2.2          0.00161    Down
                                                                                                                                                                                                          
  hsa04668:TNF signaling pathway                                                                                                                                                                          
                                                                                                                                                                                                          
  NM_006290                                      TC06001027.hg.1   TNFAIP3       Tumor necrosis factor, alpha-induced protein 3                                                  20.2          0.00007    Up
  NM_006941                                      TC11001948.hg.1   TCF19         Transcription factor 19                                                                         8.96          0.00064    Up
  NM_001168319                                   TC06000087.hg.1   EDN1          Endothelin 1                                                                                    3.0           0.00025    Up
  NM_001145138                                   TC11001939.hg.1   RELA          V-rel reticuloendotheliosis viral oncogene homolog A (avian)                                    3.0           0.00002    Up
  NM_001244134                                   TC10002935.hg.1   MAP3K8        Mitogen-activated protein kinase kinase kinase 8                                                2.9           0.00013    Up
  NM_000214                                      TC20000621.hg.1   JAG1          Jagged 1                                                                                        2.7           0.00019    Up
  NM_000963                                      TC01003638.hg.1   PTGS2         Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)           2.6           0.02677    Up
  NM_001166                                      TC11000957.hg.1   BIRC2         Baculoviral IAP repeat containing 2                                                             2.3           0.00069    Up
  NM_000600                                      TC05001366.hg.1   IL6           Interleukin-6                                                                                   2.2           0.00002    Up
  NM_182810                                      TC22000317.hg.1   ATF4          Activating transcription factor 4 (tax-responsive enhancer element B67)                         2.2           0.00548    Up
  NM-029914                                      TC61000040.hg.1   UBIAD1        UbiA prenyltransferase domain containing 1                                                      −16.88        0.00108    Down
  NM_001256045                                   TC03001824.hg.1   PIK3CB        Phosphoinositide-3-kinase, catalytic, beta polypeptide                                          −4.7          0.00000    Down
  NM_001065                                      TC12001135.hg.1   TNFRSF1A      Tumor necrosis factor receptor superfamily, member 1A                                           −4.0          0.00035    Down
  NM_002758                                      TC17000807.hg.1   MAP2K6        Mitogen-activated protein kinase kinase 6                                                       −4.0          0.00021    Down
  NM_002982                                      TC17000383.hg.1   CCL2          Chemokine (C-C motif) ligand 2                                                                  −2.6          0.03428    Down
  NM_001114172                                   TC01002616.hg.1   PIK3R3        Phosphoinositide-3-kinase, regulatory subunit 3 (gamma)                                         −2.3          0.00083    Down
  NM_005027                                      TC19002628.hg.1   PIK3R2        Phosphoinositide-3-kinase, regulatory subunit 2 (beta)                                          −2.3          0.00044    Down
  NM_001136153                                   TC06004121.hg.1   ATF6B         Activating transcription factor 6 beta                                                          −2.1          0.00045    Down
  NM_001199427                                   TC14000786.hg.1   TRAF3         TNF receptor-associated factor 3 (TRAF3)                                                        −2.1          0.00073    Down
                                                                                                                                                                                                          
  hsa04152:AMPK signaling pathway                                                                                                                                                                         
                                                                                                                                                                                                          
  NM_003749                                      TC13000871.hg.1   IRS2          Insulin receptor substrate 2                                                                    3.5           0.00044    Up
  NM_000875                                      TC15000949.hg.1   IGF1R         Insulin-like growth factor 1 receptor                                                           3.5           0.00188    Up
  NM_181715                                      TC01003280.hg.1   CRTC2         CREB regulated transcription coactivator 2                                                      3.0           0.00176    Up
  NM_006253                                      TC12000936.hg.1   PRKAB1        Protein kinase, AMP-activated, beta 1 non-catalytic subunit                                     2.7           0.00031    Up
  NM_012238                                      TC10000400.hg.1   SIRT1         Sirtuin 1                                                                                       2.5           0.00023    Up
  NM_001018053                                   TC01001731.hg.1   PFKFB2        6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2                                           2.4           0.00008    Up
  NM_000859                                      TC05000363.hg.1   HMGCR         3-hydroxy-3-methylglutaryl-CoA reductase                                                        −4.8          0.00001    Down
  NM_001256045                                   TC03001824.hg.1   PIK3CB        Phosphoinositide-3-kinase, catalytic, beta polypeptide                                          −4.7          0.00000    Down
  NM_005063                                      TC10000721.hg.1   SCD           Stearoyl-CoA desaturase (delta-9-desaturase)                                                    −4.6          0.00323    Down
  NM_001237                                      TC04001516.hg.1   CCNA2         Cyclin A2                                                                                       −3.5          0.00007    Down
  NM_001199756                                   TC01001771.hg.1   PPP2R5A       Protein phosphatase 2, regulatory subunit B′, alpha                                             −2.8          0.00000    Down
  NM_004104                                      TC17001973.hg.1   FASN          Fatty acid synthase                                                                             −2.6          0.00024    Down
  NM_198834                                      TC17001406.hg.1   ACACA         Acetyl-CoA carboxylase alpha                                                                    −2.6          0.00073    Down
  NM_005027                                      TC19002628.hg.1   PIK3R2        Phosphoinositide-3-kinase, regulatory subunit 2                                                 −2.3          0.00044    Down
  NM_001114172                                   TC01002616.hg.1   PIK3R3        Phosphoinositide-3-kinase, regulatory subunit 3 (gamma)                                         −2.3          0.00083    Down
  NM_005037                                      TC03000069.hg.1   PPARG         Peroxisome proliferator-activated receptor gamma                                                −2.1          0.00108    Down
  NM_001177562                                   TC11002284.hg.1   PPP2R1B       Protein phosphatase 2, regulatory subunit A                                                     −2.0          0.01473    Down
                                                                                                                                                                                                          
  hsa04621:NOD-like receptor signaling pathway                                                                                                                                                            
                                                                                                                                                                                                          
  NM_006290                                      TC06001027.hg.1   TNFAIP3       Tumor necrosis factor, alpha-induced protein 3                                                  20.2          0.00007    Up
  NM_001562                                      TC11002293.hg.1   IL18          Interleukin-18                                                                                  3.1           0.00033    Up
  NM_001145138                                   TC11001939.hg.1   RELA          V-rel reticuloendotheliosis viral oncogene homolog A                                            3.0           0.00002    Up
  NM_001166                                      TC11000957.hg.1   BIRC2         Baculoviral IAP repeat containing 2                                                             2.3           0.00069    Up
  NM_004620                                      TC11001560.hg.1   TRAF6         TNF receptor-associated factor 6, E3 ubiquitin protein ligase                                   2.3           0.00000    Up
  NM_000600                                      TC05001366.hg.1   IL6           Interleukin-6                                                                                   2.2           0.00002    Up
  NM_001006600                                   TC05000280.hg.1   ERBB2IP       Erbb2 interacting protein                                                                       −3.1          0.00030    Down
  NM_002982                                      TC17000383.hg.1   CCL2          Chemokine (C-C motif) ligand 2                                                                  −2.6          0.03428    Down
  NM_001017963                                   TC14001526.hg.1   HSP90AA1      Heat shock protein 90 kDa alpha (cytosolic), class A member 1                                   −2.5          0.00029    Down
